Anne-Marie Bonneau

Title: The Innovations of Anne-Marie Bonneau

Introduction

Anne-Marie Bonneau is a notable inventor based in Longueil, Canada. She has made significant contributions to the field of virology, particularly in the production and purification of viral envelope proteins for vaccine use. With a total of 3 patents, her work has had a substantial impact on vaccine development.

Latest Patents

Anne-Marie's latest patents focus on the production of immunogenic envelope glycoproteins derived from enveloped viruses, specifically from the paramyxoviridae family, including PIV-3 and RSV. The process involves culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from tissue culture, solubilizing the envelope glycoproteins, and subsequently isolating the solubilized envelope glycoproteins through chromatography. This innovative approach enhances the efficacy of vaccines by ensuring the purity and effectiveness of the viral components used.

Career Highlights

Throughout her career, Anne-Marie has worked with prominent companies in the biotechnology and pharmaceutical sectors. Notable among these are Connaught Laboratories Limited and Aventis Pasteur Limited. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in vaccine development.

Collaborations

Anne-Marie has collaborated with esteemed colleagues, including Mary E. Ewasyshyn and Barry Ian Caplan. These partnerships have fostered a collaborative environment that has been essential for advancing her research and innovations.

Conclusion

Anne-Marie Bonneau's contributions to the field of virology and vaccine development are commendable. Her innovative patents and collaborations highlight her dedication to improving public health through scientific advancements.